GO:0005007 fibroblast growth factor receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005007 (fibroblast growth factor receptor activity) is a molecular function defined as combining with a fibroblast growth factor receptor ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity.
• FGFR signaling is a central driver of proliferation, differentiation, survival, and metabolic reprogramming, and its dysregulation is implicated across many cancers and metabolic diseases.
• The four canonical FGFRs (FGFR1-4) are receptor tyrosine kinases that dimerize upon FGF binding and autophosphorylate to recruit downstream adaptors.
• FGFR inhibitors are an active clinical and patent landscape, with resistance mechanisms emerging in cholangiocarcinoma and other tumors.
• FGFR signaling also controls phosphate sensing and cholesterol storage, linking this GO term to kidney and metabolic biology.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect FGFR pathway causality and to validate therapeutic targets.
Description
Fibroblast growth factor receptor activity (GO:0005007) is a molecular function that enables a cell to bind an FGF ligand and transmit that signal across the plasma membrane to initiate a change in cell activity. This activity is executed by the FGFR family of receptor tyrosine kinases, which convert extracellular FGF cues into intracellular phosphorylation cascades that control proliferation, differentiation, migration, and survival. Because the term is defined at the level of ligand recognition and signal transmission, it sits at the interface of extracellular growth factor sensing and intracellular signaling, making it a recurring node in cancer, metabolic, and developmental research. The biomedical importance of GO:0005007 is difficult to overstate. Aberrant FGFR signaling is a recognized oncogenic driver across multiple tumor types, and FGFR inhibitors have entered clinical practice and patent portfolios, while resistance mechanisms continue to limit durable responses. Beyond oncology, FGFR activity participates in metabolic dysfunction-associated fatty liver disease, phosphate sensing, and cholesterol storage, indicating that this molecular function is embedded in systemic physiology rather than being a purely proliferative switch. For researchers, GO:0005007 provides a precise annotation target when interpreting transcriptomic, proteomic, or functional-genomic data. Assigning a gene product to this term requires evidence of ligand binding and signal transmission, not merely sequence similarity. This distinction matters when designing CRISPR models, because loss-of-function, point-mutation, and knock-in strategies test different aspects of receptor activity and downstream output.
fibroblast growth factor receptor activity At A Glance
| GO ID | GO:0005007 |
|---|---|
| GO term | fibroblast growth factor receptor activity |
| Ontology | molecular_function |
| Synonym | FGF-activated receptor activity; FGFR; FGF receptor activity; fibroblast growth factor-activated receptor activity |
| Definition | Combining with a fibroblast growth factor receptor ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity. |
| Major function | Ligand-activated transmembrane signaling by FGFR family receptor tyrosine kinases |
| Representative receptors | FGFR1, FGFR2, FGFR3, FGFR4 |
| Representative ligands | FGF1, FGF2, FGF4, FGF8, FGF19, FGF21, FGF23 |
| Disease relevance | Cancer, cholangiocarcinoma resistance, metabolic dysfunction-associated fatty liver disease, phosphate homeostasis |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, phospho-signaling assays, RNA-seq, proteomics |
What Is GO:0005007?
In practical terms, GO:0005007 describes the function of a receptor that binds a fibroblast growth factor ligand and, upon binding, transmits a signal across the plasma membrane to change cell behavior. The QuickGO definition emphasizes two inseparable features: ligand recognition and transmembrane signal transduction. A protein annotated with this term is therefore expected to act as a cell-surface receptor for FGF ligands and to initiate intracellular signaling, rather than merely sequestering or transporting FGFs. This function is typically associated with receptor tyrosine kinase activity and is a prerequisite for downstream events such as MAPK, PI3K-AKT, and PLCgamma pathway activation.
Why Is fibroblast growth factor receptor activity Important in Cell Biology?
GO:0005007 is important because it defines the entry point of one of the most pleiotropic signaling systems in human biology. FGFR activity translates extracellular FGF cues into transcriptional and metabolic programs, and its dysregulation is causally linked to tumor initiation, progression, and therapy resistance. At the same time, FGFR signaling contributes to normal metabolic and endocrine functions, including phosphate sensing and lipid storage, so the same molecular function can be protective or pathogenic depending on context. This dual nature makes precise annotation and experimental modeling essential for both basic discovery and therapeutic development.
• FGFR activity is a validated oncogenic driver across multiple cancers, making GO:0005007 a high-value target for drug discovery.
• FGFR inhibitors are clinically relevant and actively patented, but resistance mechanisms such as gatekeeper mutations and bypass signaling limit efficacy.
• FGFR signaling modulates metabolic dysfunction-associated fatty liver disease, linking this molecular function to hepatometabolic disease.
• FGFR activity participates in phosphate sensing, connecting it to mineral and kidney physiology.
• FGFR signaling can promote cholesterol storage in a SOAT1-dependent manner in mammary tumor cells, linking it to lipid metabolism and invasion.
• FGFR signaling is important in GIST and soft tissue sarcomas, expanding its disease relevance beyond carcinomas.
• Translational research targeting FGFR signaling requires robust preclinical models and biomarkers.
• GO:0005007 annotation helps interpret functional genomics screens and prioritize candidate drivers.
• CRISPR-based models enable causal testing of FGFR pathway components in isogenic backgrounds.
• Understanding FGFR activity supports development of combination therapies to overcome resistance.
Molecular Mechanism of fibroblast growth factor receptor activity
Ligand binding and receptor dimerization
In simple terms: An FGF ligand grabs two FGFR molecules and pulls them together, which switches the receptor on.
The first step in fibroblast growth factor receptor activity is binding of an FGF ligand to the extracellular domain of an FGFR. This event promotes receptor dimerization and brings the intracellular kinase domains into proximity, a prerequisite for activation. Heparan sulfate proteoglycans often act as co-receptors that stabilize the ligand-receptor complex. Because the QuickGO definition requires both ligand combination and signal transmission, dimerization is a defining mechanistic step rather than a downstream consequence.
Autophosphorylation and kinase activation
In simple terms: Once paired, the receptors phosphorylate each other to fully turn on their enzymatic activity.
Dimerization enables trans-autophosphorylation of tyrosine residues in the FGFR intracellular domain. These phosphotyrosines serve as docking sites for adaptor proteins and also stabilize the active kinase conformation. This step converts ligand binding into a biochemical signal and is the core enzymatic event of GO:0005007. Dysregulation of this step, through mutation or overexpression, is a common oncogenic mechanism.
Downstream signaling cascades
In simple terms: The activated receptor passes the message to several internal communication lines that change what the cell does.
Phosphorylated FGFR recruits adaptors such as FRS2 and activates RAS-MAPK, PI3K-AKT, and PLCgamma pathways. These cascades alter transcription, metabolism, and cytoskeletal dynamics, producing the change in cell activity specified by the GO definition. The breadth of downstream outputs explains why FGFR activity influences proliferation, survival, migration, and differentiation.
Signal attenuation and feedback
In simple terms: The cell has brakes that shut the receptor signal off after it has done its job.
FGFR signaling is attenuated by receptor internalization, ubiquitination, and dephosphorylation, as well as by negative feedback loops such as Sprouty and MAPK phosphatases. Loss of these brakes can prolong GO:0005007 activity and contribute to disease. Feedback regulation is also a mechanism of resistance to FGFR inhibitors, because bypass pathways can restore downstream signaling.
Context-dependent outputs
In simple terms: The same receptor can tell different cells to do different things depending on the tissue.
The functional outcome of fibroblast growth factor receptor activity depends on the FGF ligand, the FGFR isoform, and the cellular context. In hepatocytes, FGFR signaling contributes to metabolic dysfunction-associated fatty liver disease, while in kidney tissue it participates in phosphate sensing, and in mammary tumor cells it can modulate cholesterol storage and invasion. This context dependence is why GO:0005007 is annotated as a molecular function rather than a single biological process.
Key Genes Involved in GO:0005007 fibroblast growth factor receptor activity
The following genes encode receptors, ligands, and core signaling components that collectively execute or regulate fibroblast growth factor receptor activity (GO:0005007).
| Gene | Major Role | Research Relevance |
|---|---|---|
| FGFR1 | Receptor tyrosine kinase that binds FGF ligands and transmits signals | Frequent target in cancer and developmental studies; KO and point-mutation models |
| FGFR2 | Receptor tyrosine kinase with roles in epithelial and skeletal biology | Oncogenic fusions and mutations; relevant to cholangiocarcinoma and other tumors |
| FGFR3 | Receptor tyrosine kinase regulating proliferation and differentiation | Skeletal and oncogenic roles; useful for knock-in disease models |
| FGFR4 | Receptor tyrosine kinase with metabolic and oncogenic functions | Target in liver and metabolic studies; KO models informative |
| FGF1 | Prototypical FGF ligand that activates multiple FGFRs | Used to stimulate FGFR activity in vitro and in vivo |
| FGF2 | Ligand involved in proliferation and angiogenesis | Common experimental ligand for FGFR activation assays |
| FGF19 | Endocrine FGF ligand with metabolic roles | Relevant to metabolic dysfunction-associated fatty liver disease |
| FGF21 | Endocrine FGF ligand regulating metabolism | Studied in metabolic disease and FGFR signaling |
| FGF23 | Endocrine FGF ligand controlling phosphate homeostasis | Central to phosphate sensing via FGFR |
| FRS2 | Adaptor protein recruited to activated FGFR | Key node for downstream MAPK and PI3K signaling |
| KLB | Beta-Klotho co-receptor for endocrine FGFs | Required for FGF19/FGF21/FGF23 signaling specificity |
| HSPG2 | Heparan sulfate proteoglycan co-receptor | Modulates ligand-receptor complex formation |
| SOAT1 | Enzyme linked to cholesterol storage downstream of FGFR | Connects FGFR signaling to lipid metabolism and invasion |
| SPRY2 | Negative feedback regulator of FGFR signaling | Modulates duration and intensity of GO:0005007 output |
| PTPN11 | Phosphatase/adaptor in RAS-MAPK signaling | Downstream effector and resistance node |
| KRAS | Small GTPase downstream of FGFR | Bypass resistance mechanism to FGFR inhibitors |
| PIK3CA | Kinase in PI3K-AKT pathway downstream of FGFR | Effector of survival signaling and resistance |
| BRAF | Kinase in MAPK pathway downstream of FGFR | Effector of proliferative signaling and resistance |
How Is fibroblast growth factor receptor activity Regulated?
Fibroblast growth factor receptor activity is regulated at multiple levels. Ligand availability, heparan sulfate co-receptor presentation, and receptor dimerization control the initiation of signaling, while phosphorylation, ubiquitination, and internalization control its duration. Negative feedback loops involving Sprouty proteins and MAPK phosphatases attenuate the signal, and their loss can prolong FGFR activity. In disease contexts, resistance to FGFR inhibitors frequently arises through bypass activation of downstream pathways such as RAS-MAPK and PI3K-AKT, illustrating that regulation of GO:0005007 extends beyond the receptor itself. Metabolic and endocrine inputs, including FGF19, FGF21, and FGF23 with KLB, further tune FGFR activity in a tissue-specific manner.
fibroblast growth factor receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FGFR2 | Cholangiocarcinoma and resistance to FGFR inhibitors | Knock-in of resistance mutations; KO of FGFR2 in cholangiocarcinoma lines |
| FGFR3 | Skeletal disorders and oncogenic proliferation | Point-mutation knock-in to model activating mutations |
| FGFR4 | Metabolic dysfunction-associated fatty liver disease | KO and overexpression in hepatocyte models |
| FGF23 | Phosphate homeostasis disorders | Knock-in and KO models to study endocrine FGFR signaling |
| SOAT1 | Cholesterol storage and mammary tumor invasion | KO and overexpression in breast cancer models |
FGFR activity in cancer
Aberrant fibroblast growth factor receptor activity is a well-established oncogenic mechanism. FGFR alterations, including amplification, mutation, and fusion, drive tumor proliferation and survival across multiple cancers, and FGFR inhibitors have been developed as targeted therapies. The molecular targeting of the FGFR pathway is an active area of drug development, with patent activity reflecting sustained interest. In GIST and soft tissue sarcomas, FGFR signaling contributes to tumor biology and is being explored as a therapeutic vulnerability.
Resistance to FGFR inhibitors
Despite clinical activity, resistance to FGFR inhibitors limits durable benefit. Resistance mechanisms in cholangiocarcinoma include secondary FGFR2 mutations, bypass signaling through RAS-MAPK and PI3K-AKT, and activation of alternative receptor tyrosine kinases. These mechanisms underscore the need for combination strategies and for experimental models that can test causality of specific pathway nodes.
Metabolic and endocrine roles
FGFR signaling extends beyond oncology. It contributes to metabolic dysfunction-associated fatty liver disease, where FGF19 and FGF21 signaling through FGFR-KLB complexes influences lipid and glucose metabolism. FGFR activity also participates in phosphate sensing, with FGF23 acting as a key endocrine regulator. In mammary tumor cells, FGFR signaling can modulate cholesterol storage in a SOAT1-dependent manner to promote invasion, linking this molecular function to lipid metabolism.
From fibroblast growth factor receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is FGFR1 required for ligand-induced proliferation? | CRISPR knockout of FGFR1 in isogenic cell lines |
| Does a specific FGFR2 mutation confer resistance? | Point-mutation knock-in of the resistance allele |
| Can a tagged FGFR report real-time signaling? | Knock-in of an epitope- or fluorescent-tagged FGFR |
| Does FGFR overexpression drive transformation? | Overexpression of wild-type or mutant FGFR |
| Which downstream nodes mediate FGFR output? | Knockout of FRS2, KRAS, or PIK3CA in FGFR-driven models |
| Does FGFR signaling alter lipid storage? | KO or overexpression of FGFR with SOAT1 readouts |
How to Study the fibroblast growth factor receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot for phospho-FGFR | Receptor autophosphorylation | Confirm ligand-induced activation |
| Phospho-ERK/ATK assays | Downstream pathway activation | Test signaling output after CRISPR edits |
| RNA-seq | Transcriptional changes | Define FGFR-dependent gene programs |
| CRISPR library screening | Genes modifying FGFR-dependent growth | Identify resistance and synthetic lethal nodes |
| Co-immunoprecipitation | Protein-protein interactions | Map FGFR adaptor complexes |
| Proximity labeling | Spatial interactome | Discover co-receptors and regulators |
| Live-cell imaging | Receptor trafficking and dimerization | Visualize dynamic FGFR activity |
| Metabolic assays | Lipid or phosphate readouts | Link FGFR to metabolism |
Phospho-signaling assays
Because GO:0005007 is defined by signal transmission, measuring receptor autophosphorylation and downstream phospho-ERK or phospho-AKT is a direct functional readout. These assays are used to confirm ligand-induced activation and to test the impact of CRISPR edits on FGFR activity.
Transcriptomics and functional genomics
RNA-seq after FGF stimulation or FGFR perturbation reveals the transcriptional programs downstream of GO:0005007. CRISPR library screening can identify genes that modify FGFR-dependent proliferation or drug response, providing a unbiased view of pathway wiring.
Proteomics and interactomics
Affinity purification or proximity labeling of FGFR complexes can identify adaptors, co-receptors, and feedback regulators. Proteomic profiling of phosphotyrosine sites quantifies the immediate signaling output of receptor activation.
Imaging and localization
Fluorescence microscopy of tagged FGFRs can visualize dimerization, internalization, and trafficking. These methods complement biochemical assays by showing where and when fibroblast growth factor receptor activity occurs within the cell.
How CRISPR Can Be Used to Study GO:0005007 fibroblast growth factor receptor activity
Knockout
CRISPR knockout of FGFR genes or downstream effectors is used to test whether a component is required for fibroblast growth factor receptor activity and its biological outputs. Isogenic KO lines allow clean comparison of ligand-induced signaling and proliferation, and can validate candidate drivers from screens.
Point Mutation
Point-mutation models introduce specific amino acid changes to mimic activating or resistance mutations. These are particularly valuable for studying FGFR2 gatekeeper mutations associated with inhibitor resistance and for dissecting kinase-dependent versus kinase-independent functions.
Knock-in
Knock-in of tags, reporters, or disease alleles enables tracking of endogenous FGFR expression and signaling. Tagged knock-in lines can be used for imaging, proteomics, and drug-response studies without overexpression artifacts.
Overexpression
Overexpression of wild-type or mutant FGFR can model oncogenic amplification and test whether increased receptor dosage is sufficient to transform cells. Overexpression systems are also useful for biochemical studies of receptor activation and downstream signaling.
How EDITGENE Supports fibroblast growth factor receptor activity Research
Researchers studying fibroblast growth factor receptor activity-related genes often need to determine whether a candidate gene is causally involved in ligand sensing, signal transmission, or downstream output. CRISPR-based models provide the isogenic context required to move from correlation to causation, and EDITGENE supports this workflow with validated cell engineering services.
Contact EDITGENE today to design your custom CRISPR model for fibroblast growth factor receptor activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| FGFRL1 Knockout HEK293 Cell Line | EDJ-KQ11355 | Human | 53834 | Details Get a Quote |
| FGFR1 Knockout HEK293 Cell Line | EDJ-KQ17681 | Human | 2260 | Details Get a Quote |
| FGFR2 Knockout HEK293 Cell Line | EDJ-KQ17682 | Human | 2263 | Details Get a Quote |
| FGFR4 Knockout HEK293 Cell Line | EDJ-KQ17698 | Human | 2264 | Details Get a Quote |
| FGFR3 Knockout HEK293 Cell Line | EDJ-KQ17818 | Human | 2261 | Details Get a Quote |
| FGFR2 Knockout HCT 116 Cell Line | EDJ-KQ18098 | Human | 2263 | Details Get a Quote |
| FGFR1 Knockout A-549 Cell Line | EDJ-KQ19175 | Human | 2260 | Details Get a Quote |
| FGFR1 Knockout HCT 116 Cell Line | EDJ-KQ19176 | Human | 2260 | Details Get a Quote |
| FGFR1 Knockout HeLa Cell Line | EDJ-KQ19177 | Human | 2260 | Details Get a Quote |
| FGFR3 Knockout A-549 Cell Line | EDJ-KQ19179 | Human | 2261 | Details Get a Quote |
| FGFR3 Knockout HCT 116 Cell Line | EDJ-KQ19180 | Human | 2261 | Details Get a Quote |
| FGFR3 Knockout HeLa Cell Line | EDJ-KQ19181 | Human | 2261 | Details Get a Quote |
| FGFR4 Knockout A-549 Cell Line | EDJ-KQ19182 | Human | 2264 | Details Get a Quote |
| FGFR4 Knockout HCT 116 Cell Line | EDJ-KQ19183 | Human | 2264 | Details Get a Quote |
| FGFR4 Knockout HeLa Cell Line | EDJ-KQ19184 | Human | 2264 | Details Get a Quote |
Displaying Records 1 To 15 Of 29 Records
Frequently Asked Questions About fibroblast growth factor receptor activity
What is fibroblast growth factor receptor activity?
Fibroblast growth factor receptor activity (GO:0005007) is a molecular function in which a receptor binds an FGF ligand and transmits a signal across the plasma membrane to initiate a change in cell activity.
What genes are involved in fibroblast growth factor receptor activity?
Key genes include FGFR1, FGFR2, FGFR3, FGFR4, FGF ligands such as FGF1, FGF2, FGF19, FGF21, and FGF23, co-receptors such as KLB and HSPG2, and downstream effectors such as FRS2, KRAS, and PIK3CA.
What is the GO ID for fibroblast growth factor receptor activity?
The GO ID is GO:0005007, and the ontology aspect is molecular_function.
How is fibroblast growth factor receptor activity regulated?
It is regulated by ligand availability, co-receptor presentation, receptor dimerization, autophosphorylation, internalization, and negative feedback loops such as Sprouty and MAPK phosphatases.
Why is FGFR signaling important in cancer?
Aberrant FGFR signaling drives proliferation and survival in multiple cancers, and FGFR inhibitors are used clinically, although resistance can emerge.
What diseases are linked to FGFR activity?
FGFR activity is linked to multiple cancers, cholangiocarcinoma resistance, metabolic dysfunction-associated fatty liver disease, phosphate homeostasis disorders, and lipid metabolism in breast cancer.
How do researchers study fibroblast growth factor receptor activity?
Common methods include phospho-signaling assays, RNA-seq, proteomics, imaging, and CRISPR knockout, point-mutation, knock-in, and overexpression models.
What is the role of FGFR in cholangiocarcinoma resistance?
Resistance to FGFR inhibitors in cholangiocarcinoma can involve secondary FGFR2 mutations and bypass signaling through RAS-MAPK and PI3K-AKT pathways.
Can CRISPR be used to model FGFR mutations?
Yes, CRISPR point-mutation and knock-in models can introduce specific FGFR mutations to study activation, resistance, and downstream signaling.
What is the connection between FGFR and metabolism?
FGFR signaling contributes to metabolic dysfunction-associated fatty liver disease, phosphate sensing, and cholesterol storage, linking GO:0005007 to systemic metabolism.
Conclusion
GO:0005007 (fibroblast growth factor receptor activity) defines a central molecular function that converts extracellular FGF cues into intracellular signals controlling proliferation, metabolism, and survival. Its dysregulation is implicated in cancer, resistance to targeted therapy, and metabolic disease, making it a high-priority area for mechanistic and translational research. Precise experimental models are essential to dissect the causal roles of FGFR pathway components. CRISPR knockout, point-mutation, knock-in, and overexpression strategies, combined with phospho-signaling, transcriptomic, proteomic, and imaging readouts, provide a robust framework for studying this GO term and for developing new therapeutic approaches.
References
- 1. Marseglia G et al.. 2019. Fibroblast growth factor receptor inhibitors: patent review (2015-2019).. Expert Opin Ther Pat 29(12):965-977 PMID: 31679402
- 2. Chu Y et al.. 2025. Fibroblast growth factor receptor signaling in metabolic dysfunction-associated fatty liver disease: Pathogenesis and therapeutic targets.. Pharmacol Ther 269:108844 PMID: 40113178
- 3. Shan KS et al.. 2024. Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers.. Int J Mol Sci 25(2) PMID: 38255923
- 4. Napolitano A et al.. 2021. Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas.. Cells 10(6) PMID: 34204560
- 5. Holzmann K et al.. 2019. Importance of Translational Research for Targeting Fibroblast Growth Factor Receptor Signaling in Cancer.. Cells 8(10) PMID: 31581712
- 6. Takashi Y et al.. 2020. Fibroblast growth factor receptor as a potential candidate for phosphate sensing.. Curr Opin Nephrol Hypertens 29(4):446-452 PMID: 32427693
- 7. Tuokkola JE et al.. 2025. Fibroblast growth factor receptor signaling modulates cholesterol storage in a SOAT1-dependent manner to promote mammary tumor cell invasion.. Breast Cancer Res 27(1):132 PMID: 40665359
- 8. Lamarca A et al.. 2023. Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma.. Cancer Treat Rev 121:102627 PMID: 37925878
